Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
9 search results for:

Empagliflozin/Linagliptin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 02-03-2023 | Empagliflozin | News | Article

    DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

    Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

    Author:
    Eleanor McDermid
    Published in:
    Lancet Diabetes Endocrinol 2023; doi:10.1016/S2213-8587(22)00387-4 Lancet Diabetes Endocrinol 2023; doi:10.1016/S2213-8587(23)00030-X
  2. 06-28-2017 | Topic page

    Empagliflozin_Linagliptin

  3. 04-05-2022 | Medications | At a glance | Article
    At a glance

    Medications for pediatric type 2 diabetes: What’s approved, what’s coming up?

    Linagliptin is currently undergoing testing in children and adolescents , in a trial also testing the sodium-glucose cotransporter (SGLT)2 inhibitor empagliflozin.

    Author:
    Eleanor McDermid
  4. 12-06-2016 | Empagliflozin/Linagliptin | News | Article

    Empagliflozin effective as add-on to dual oral therapy

    The sodium–glucose cotransporter 2 inhibitor empagliflozin significantly improves glycemic control in patients with type 2 diabetes who are already taking linagliptin and metformin, shows a randomized trial.

    Published in:
    Diabetes Care 2016; Advance online publication
  5. 06-12-2018 | Empagliflozin | Article

    Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

    In this work, we aimed to assess the relative treatment effects of empagliflozin versus sitagliptin and saxagliptin (dipeptidyl peptidase-4 (DPP-4)

  6. 06-29-2020 | SGLT2 inhibitors | News | Article

    CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

    Sitagliptin was the most common DPP-4 inhibitor (49% of total exposure time), followed by linagliptin (20%), and saxagliptin (11%).

    Author:
    Laura Cowen
    Published in:
    Lancet Diabetes Endocrinol 2020; 8 : 606–615
  7. 06-05-2018 | Cardiovascular outcomes | Review | Article

    Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

    Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

  8. 10-23-2017 | Cardiovascular disorders | Review | Article

    Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

    Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

  9. 10-11-2017 | Cardiovascular disorders | Review | Article

    Updates on cardiovascular outcome trials in diabetes

    Schnell O et al. Cardiovasc Diabetol 2017; 16: 128. doi: 10.1186/s12933-017-0610-y

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.